Citations

Showing 10 of 108162 citations.

Dry Mouth: An Overlooked Autonomic Symptom of Parkinson's Disease
Cersósimo, María G. , Raina, Gabriela B. , Calandra, Cristian , Pellene, Alejandro, Gutiérrez, Cristiam, Micheli, Federico , Benarroch, Eduardo E.

Mayo Clinic

Journal of Parkinson’s Disease | December 3, 2019 | Volume: 1 | Issue: 2 | Pages: 169-173

10.3233/jpd-2011-11021 | PMID 23939300 Get It

There is involvement of salivary glands by α-synuclein pathology in PD. However, the prevalence of dry mouth has not been systematically assessed in these patients. We studied 97 PD patients and 86 controls using a structured questionnaire. Dry mouth was reported by 60.8% of PD patients and 27.9% of controls (p < 0.0001). Dry mouth and drooling coexisted in 30% of cases. Only 12% of patients had reported dry mouth to their physicians. Dry mouth is a frequent but underreported symptom and may be an early manifestation of autonomic involvement in PD.
2019 sickle cell disease guidelines by the American Society of Hematology: methodology, challenges, and innovations
Murad, M. Hassan , Lang, Eddy , Meerpohl, Joerg J , DeBaun, Michael R. , Lanzkron, Sophie , Webb, Starr, Murad, M Hassan , Meerpohl, Joerg J , DeBaun, Michael R , Liem, Robert I. , Akl, Elie A. , Tisdale, John , Brandow, Amanda M. , Chou, Stella T. , Mustafa, Reem A

Mayo Clinic

Blood Advances | December 3, 2019 | Volume: 3 | Issue: 23 | Pages: 3945-3950

10.1182/bloodadvances.2019000931 | PMID 31794603 Get It

Abstract The American Society of Hematology (ASH) convened 5 guideline panels to develop clinical practice recommendations addressing 5 management areas of highest importance to individuals living with sickle cell disease: pain, cerebrovascular complications, pulmonary and kidney complications, transfusion, and hematopoietic stem cell transplant. Panels were multidisciplinary and consisted of patient representatives, content experts, and methodologists. The Mayo Clinic Evidence-Based Practice Center conducted systematic reviews based on a priori selected questions. In this exposition, we describe the process used by ASH, including the GRADE approach (Grades of Recommendations, Assessment, Development and Evaluation) for rating certainty of the evidence and the GRADE Evidence to Decision Framework. We also describe several unique challenges faced by the guideline panels and the specific innovations and solutions used to address them, including a curriculum to train patients to engage in guideline development, dealing with the opioid crisis, and working with indirect and noncomparative evidence.
Transcriptomic Profiles of Confirmed Pediatric Tuberculosis Patients and Household Contacts Identifies Active Tuberculosis, Infection, and Treatment Response Among Indian Children
Tornheim, Jeffrey A. , Madugundu, Anil K. , Paradkar, Mandar , Fukutani, Kiyoshi F. , Queiroz, Artur T. L. , Gupte, Nikhil , Gupte, Akshay , Kinikar, Aarti , Kulkarni, Vandana , Balasubramanian, Usha, Raja, Remya , Pradhan, Neeta , Shivakumar, Shri Vijay Bala Yogendra , Valvi, Chhaya, Hanna, Luke Elizabeth , Mave, Vidya , Pandey, Akhilesh , Gupta, Amita , Team, CTRIUMPh RePORT India Study, Pandey, Akhilesh , Pandey, Akhilesh , Sreenivasamurthy, Sreelakshmi K. , Andrade, Bruno B. , Team, CTRIUMPh RePORT India Study

Mayo Clinic

The Journal of Infectious Diseases | December 3, 2019 | Volume: 221 | Issue: 10 | Pages: 1647-1658

10.1093/infdis/jiz639 | PMID 31796955 Get It

AbstractBackgroundGene expression profiling is emerging as a tool for tuberculosis diagnosis and treatment response monitoring, but limited data specific to Indian children and incident tuberculosis infection (TBI) exist.MethodsSixteen pediatric Indian tuberculosis cases were age- and sex-matched to 32 tuberculosis-exposed controls (13 developed incident TBI without subsequent active tuberculosis). Longitudinal samples were collected for ribonucleic acid sequencing. Differential expression analysis generated gene lists that identify tuberculosis diagnosis and tuberculosis treatment response. Data were compared with published gene lists. Population-specific risk score thresholds were calculated.ResultsSeventy-one genes identified tuberculosis diagnosis and 25 treatment response. Within-group expression was partially explained by age, sex, and incident TBI. Transient changes in gene expression were identified after both infection and treatment. Application of 27 published gene lists to our data found variable performance for tuberculosis diagnosis (sensitivity 0.38–1.00, specificity 0.48–0.93) and treatment response (sensitivity 0.70–0.80, specificity 0.40–0.80). Our gene lists found similarly variable performance when applied to published datasets for diagnosis (sensitivity 0.56–0.85, specificity 0.50–0.85) and treatment response (sensitivity 0.49– 0.86, specificity 0.50–0.84).ConclusionsGene expression profiles among Indian children with confirmed tuberculosis were distinct from adult-derived gene lists, highlighting the importance of including distinct populations in differential gene expression models.
Does Interval Between Screening and Baseline Matter in HD Cognitive Clinical Trials?
Beglinger, Leigh J., Adams, William , Langbehn, Douglas R. , Fiedorowicz, Jess G. , Caviness, John N., Biglan, Kevin , Olson, Blair, Paulsen, Jane S. , Caviness, John, Fiedorowicz, Jess G

Mayo Clinic

Journal of Huntington's Disease | December 3, 2019 | Volume: 3 | Issue: 2 | Pages: 139-144

10.3233/jhd-140100 | PMID 25062857 Get It

Background: “Practice effects” (PE), or performance improvements due to prior exposure to testing, are known to confound cognitive test results, particularly when short intervals occur between two test sessions. Objective: We examined two subsamples with short or long re-test intervals from a recent clinical trial. Methods: Thirty-four non-depressed adults with mild Huntington Disease (HD) participated. Three cognitive tests were administered at screening and again at baseline, before active treatment randomization. Half the sample had a 24-hour retest interval while the other half was >6-days. Results: The two groups differed on demographic/clinical factors (age, Total Motor Score and Total Functional Capacity). After controlling for age and motor score, PE differences were found on three of the five UHDRS cognitive tests: the longer interval group showed larger PE on Symbol-Digit Modalities and Stroop color, while the rapid interval group had larger PE on Stroop interference. Controlling for screening cognitive performance yielded similar results. Conclusions: Length of interval between screening and baseline visits and level of disease severity may influence stability of UHDRS cognitive test results in clinical trials in HD.
Calcification and ossification in conventional schwannoma: A clinicopathologic study of 32 cases
Din, Nasir Ud , Fritchie, Karen , Tariq, Muhammad Usman , Ahmed, Arsalan , Ahmad, Zubair , Tariq, Muhammad U

Mayo Clinic

Neuropathology | December 3, 2019 | Volume: 40 | Issue: 2 | Pages: 144-151

10.1111/neup.12622 | PMID 31793063 Get It

Calcification and ossification are uncommon in schwannomas; however, when present these findings may cause diagnostic confusion with other mesenchymal tumors which more frequently harbor these features. We sought to better characterize the type and rate of calcification and ossification in schwannomas. Cases of schwannoma diagnosed at our institution from 2005 to 2019 were reviewed to determine the type and amount of calcification and ossification present. Of 2116 total cases of schwannoma reported during the study period, 38 cases harbored calcification or ossification per the pathology report. Thirty‐two of the 38 cases had slides available for review, of which 27 (84.3%) showed calcification, nine showed ossification (28.1%), and four (12.5%) cases demonstrated both. Foci of ossification typically occurred adjacent to large vessels. Of the 27 cases showing calcification, coarse dystrophic calcification was seen in 22 cases, psammomatous calcification in nine cases, and combined dystrophic and psammomatous calcification was seen in four cases. Cases with psammomatous calcification predominantly occurred in spinal roots and cerebellopontine angle of a younger age group with almost equal gender distribution. All four cases tested for protein kinase cyclic adenosine monophosphate‐dependent type I regulatory subunit alpha immunohistochemical stain demonstrated retained expression. We confirm that calcification and ossification are rare findings in schwannoma. Awareness that these features may be present in these tumors will prevent misdiagnosis and ensure appropriate clinical management.
Genetic Factors in Acute Myeloid Leukemia With Myelodysplasia-Related Changes
Fang, Hong , He, Rong , Chiu, April , Viswanatha, David S., Patnaik, Mrinal S, Reichard, Kaaren K. , Ketterling, Rhett P. , Patnaik, Mrinal S

Mayo Clinic

American Journal of Clinical Pathology | December 3, 2019 | Volume: 153 | Issue: 5 | Pages: 656-663

10.1093/ajcp/aqz206 | PMID 31977035 Get It

Abstract Objectives Acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) is a heterogeneous category with a broad range of underlying genetic abnormalities. We investigated the significance of genetic factors in a large series of AML-MRC cases. Methods The morphologic findings, genetic data, and patient outcomes were assessed in 186 AML-MRC cases. Results The median overall survival (OS) was dismal in AML-MRC patients (median, 7.6 months; 95% confidence interval, 5-10.6 months). Karyotypically normal cases and cytogenetically abnormal cases without myelodysplastic syndrome (MDS)-related cytogenetic abnormalities showed similar OS, significantly better than cases carrying MDS-related cytogenetic abnormalities. MDS-related cytogenetic abnormalities, monosomal or complex karyotype, and history of MDS or myelodysplastic/myeloproliferative neoplasm were all associated with dismal outcome. Conclusions AML-MRC predicts a poor prognosis. Our study supports the finding that the genetic profile plays a key role in determining prognosis in AML-MRC as defined according to the World Health Organization revised fourth edition (2017) diagnostic criteria.
Inhibition of PARP Sensitizes Chondrosarcoma Cell Lines to Chemo- and Radiotherapy Irrespective of the IDH1 or IDH2 Mutation Status
Venneker, Sanne , Kruisselbrink, Alwine B. , Jong, Yvonne de, Wijnen, André J. van , Danen, Erik H.J. , Bovée, Judith V.M.G. , van Wijnen, Andre J , Danen, Erik H J , Bovée, Judith V M G , Bruijn, Inge H. Briaire‐de

Mayo Clinic

Cancers | December 3, 2019 | Volume: 11 | Issue: 12 | Pages: 1918

10.3390/cancers11121918 | PMID 31810230 Get It

Chondrosarcomas are chemo- and radiotherapy resistant and frequently harbor mutations in isocitrate dehydrogenase (IDH1 or IDH2), causing increased levels of D-2-hydroxyglutarate (D-2-HG). DNA repair defects and synthetic lethality with poly(ADP-ribose) polymerase (PARP) inhibition occur in IDH mutant glioma and leukemia models. Here we evaluated DNA repair and PARP inhibition, alone or combined with chemo- or radiotherapy, in chondrosarcoma cell lines with or without endogenous IDH mutations. Chondrosarcoma cell lines treated with the PARP inhibitor talazoparib were examined for dose–response relationships, as well as underlying cell death mechanisms and DNA repair functionality. Talazoparib was combined with chemo- or radiotherapy to evaluate potential synergy. Cell lines treated long term with an inhibitor normalizing D-2-HG levels were investigated for synthetic lethality with talazoparib. We report that talazoparib sensitivity was variable and irrespective of IDH mutation status. All cell lines expressed Ataxia Telangiectasia Mutated (ATM), but a subset was impaired in poly(ADP-ribosyl)ation (PARylation) capacity, homologous recombination, and O-6-methylguanine-DNA methyltransferase (MGMT) expression. Talazoparib synergized with temozolomide or radiation, independent of IDH1 mutant inhibition. This study suggests that talazoparib combined with temozolomide or radiation are promising therapeutic strategies for chondrosarcoma, irrespective of IDH mutation status. A subset of chondrosarcomas may be deficient in nonclassical DNA repair pathways, suggesting that PARP inhibitor sensitivity is multifactorial in chondrosarcoma.
A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial of Presatovir for the Treatment of Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic-Cell Transplant Recipients
Chemaly, Roy F. , Dadwal, Sanjeet , Bergeron, Anne , Kim, Yae‐Jean , Pipavath, Sudhakar , Blanchard, Élodie , Winston, Drew J., Stiff, Patrick J. , Zuckerman, Tsila , Rahav, Galia , Small, Catherine B. , Mullane, Kathleen M. , Patron, Roberto L. , Lee, Dong‐Gun , Hirsch, Hans H. , McKevitt, Matt, Jordan, Robert , Guo, Ying , German, Polina , Porter, Danielle , Gossage, David, Watkins, Timothy R., Marty, Francisco M. , Chien, Jason W. , Ljungman, Per , Cheng, Guang‐Shing , Limaye, Ajit P. , Lachance, Silvy , Waghmare, Alpana , Boeckh, Michael

Mayo Clinic

Clinical Infectious Diseases | December 3, 2019 | Volume: 71 | Issue: 11 | Pages: 2777-2786

10.1093/cid/ciz1166 | PMID 31793991 Get It

AbstractBackgroundHematopoietic-cell transplant (HCT) recipients are at risk for severe respiratory syncytial virus (RSV) infection. We evaluated the RSV fusion inhibitor presatovir in a randomized, double-blind, Phase II trial in HCT recipients with RSV upper respiratory tract infections.MethodsPatients were stratified by lymphopenia (&lt;200/µL) and ribavirin use; were randomized, stratified by lymphopenia (&lt;200/μL) and ribavirin use, to receive oral presatovir at 200 mg or a placebo on Days 1, 5, 9, 13, and 17, and were followed through Day 28. The coprimary efficacy endpoints were the time-weighted average change in the nasal RSV viral load between Days 1 and 9 and the proportion of patients developing lower respiratory tract complications (LRTCs) through Day 28.ResultsFrom 23 January 2015 to 16 June 2017, 189 patients were randomly assigned to treatment (96 to presatovir and 93 to the placebo). Presatovir treatment, compared with the placebo treatment, did not significantly affect (prespecified α = 0.01) a time-weighted average decline in the RSV viral load from Day 1 to 9 (treatment difference, −0.33 log10 copies/mL; 95% confidence interval [CI] −.64 to −.02 log10 copies/mL; P = .040) or the progression to LRTC (11.2% vs 19.5%, respectively; odds ratio, 0.50; 95% CI, .22–1.18; P = .11). In a post hoc analysis among patients with lymphopenia, presatovir decreased LRTC development by Day 28 (2/15 [13.3%] vs 9/14 [64.3%], respectively; P = .008), compared with the placebo. Adverse events were similar for patients receiving presatovir and the placebo.ConclusionsPresatovir had a favorable safety profile in adult HCT recipients with RSV but did not achieve the coprimary endpoints. Exploratory analyses suggest an antiviral effect among patients with lymphopenia.Clinical Trials RegistrationNCT02254408; EUDRA-CT#2014-002474-36.
Chronic rhinosinusitis in eosinophilic granulomatosis with polyangiitis: clinical presentation and antineutrophil cytoplasmic antibodies
Low, Christopher M. , Keogh, Karina A., Saba, Elias S. , Gruszczynski, Nelson , Berti, Alvise , Baqir, Misbah , Smith, Byron M., Stokken, Janalee K., O’Brien, Erin K. , Gruszczynski, Nelson R, Choby, Garret , O'Brien, Erin K , Berti, Alvise , Specks, Ulrich , Choby, Garret

Mayo Clinic

International Forum of Allergy & Rhinology | December 3, 2019 | Volume: 10 | Issue: 2 | Pages: 217-222

10.1002/alr.22503 | PMID 31793227 Get It

BackgroundIn this study we aim to describe presenting characteristics and identify prognostic factors for disease resolution in patients with chronic rhinosinusitis (CRS) in the setting of eosinophilic granulomatosis with polyangiitis (EGPA).MethodsPatients evaluated at a tertiary care center with diagnoses of EGPA and CRS were identified. Descriptive statistics were obtained. Univariate analysis was used to search for prognostic factors associated with higher Lund‐Mackay score at presentation and disease resolution.ResultsForty‐four patients were included with a mean age of 52.7 (standard deviation, 14) years. Twenty‐one patients (47.7%) were female, all had a diagnosis of asthma, and 36 (83.7%) had eosinophils >10%. Common presenting symptoms for CRS included nasal discharge (87.9%) followed by nasal congestion (83.9%) and facial pain and pressure (83.8%). Medical management of CRS included systemic corticosteroids (93.2%) and systemic antibiotics (75%). Surgical intervention occurred in 29 patients (67%). Nine patients (20.5%) had resolution of sinus symptoms, including 4 with imaging confirmation. Fourteen patients (31.8%) had continued CRS, but with improved symptoms, whereas 9 patients (20.5%) had continued CRS with no improvement in symptoms. Eleven patients (25%) were lost to follow‐up and 4 (9.1%) died. Univariate analysis did not show antineutrophil cytoplasmic antibody positivity, presence of peripheral eosinophilia, gender, age, or absence of systemic therapy to be predictive of higher Lund‐Mackay score at presentation or predictive of disease resolution.ConclusionCRS in patients with EGPA is often refractory to medical and surgical management. Treatment of these patients should occur in a multidisciplinary setting.
Increasing physician activity with treadmill desks
Thompson, Warren G., Koepp, Gabriel A., Levine, James A.

Mayo Clinic

WORK: A Journal of Prevention, Assessment & Rehabilitation | December 3, 2019 | Volume: 48 | Issue: 1 | Pages: 47-51

10.3233/wor-131708 | PMID 24004766 Get It

BACKGROUND: Prolonged sitting has been shown to increase mortality and obesity. OBJECTIVE: We sought to determine whether physicians would use a treadmill desk, increase their daily physical activity and lose weight. PARTICIPANTS: 20 overweight and obese physicians aged 25 to 70 with Body Mass Index > 25. METHODS: Participants used a treadmill desk, a triaxial accelerometer, and received exercise counseling in a randomized, cross-over trial over 24 weeks. Group 1 received exercise counseling, accelerometer feedback, and a treadmill desk for 12 weeks and then accelerometer only for 12 weeks. Group 2 received an accelerometer without feedback for 12 weeks followed by exercise counseling, accelerometer feedback, and the treadmill desk for 12 weeks. RESULTS: Daily physical activity increased while using the treadmill desk compared to not using the desk by 197 kcal per day (p=0.003). The difference in weight during the two 12 week periods was 1.85 kg (p=0.03). Percent body fat was 1.9% lower while using the treadmill desk (p=0.02). There were no differences in metabolic or well-being measures. CONCLUSIONS: This study suggests that physicians will use a treadmill desk, that it does increase their activity, and that it may help with weight loss. Further studies are warranted.